WATCHMAN LEFT ATRIAL
APPENDAGE CLOSURE DEVICE
AN END TO LONG-TERM WARFARIN
After receiving the WATCHMAN Implant, 92% of patients were able to stop taking warfarin in 45 days; 99% were able to stop warfarin in 1 year1
WATCHMAN patients experienced a 72% reduction in major bleeding events vs warafin beyond 6 months post procedure
(1.0 vs 3.5 events per 100 patient-years; RR=0.28, P<0.001)2
A PROVEN PROCEDURE WITH PROVEN SAFETY
WHO WATCHMAN IS FOR
VISIT THE WATCHMAN WEBSITE TO SEE HOW WATCHMAN IS IMPLANTED
WATCHMAN™ & LAAC EDUCATIONAL OFFERINGS
Boston Scientific offers robust technical training and support for new and established WATCHMAN programs.
- WATCHMAN U technical training program for implanters
- Clinical Coordinator training program
In addition, we offer LAAC therapy education available for all HCPs.
- Advances in AF Stroke Management: Assessing Appropriate Drugs and Devices
- How to Integrate Left Atrial Appendage Closure Devices Into Clinical Practice
BE PART OF OUR VISION
Join our community to receive updates and help us advance the treatment of structural heart therapies.